300357 我武生物
已收盘 05-17 15:00:00
资讯
新帖
简况
我武生物(300357)5月10日主力资金净卖出2688.07万元
证券之星 · 05-13
我武生物(300357)5月10日主力资金净卖出2688.07万元
我武生物:公司2024年第一季度业绩有所恢复,具体经营情况详见2024年第一季度报告
证券之星 · 05-10
我武生物:公司2024年第一季度业绩有所恢复,具体经营情况详见2024年第一季度报告
我武生物:公司子公司干细胞药物在研项目目前处于临床前研究阶段,不涉及糖尿病相关适应症
证券之星 · 05-09
我武生物:公司子公司干细胞药物在研项目目前处于临床前研究阶段,不涉及糖尿病相关适应症
西南证券:给予我武生物买入评级,目标价位28.8元
证券之星 · 04-29
西南证券:给予我武生物买入评级,目标价位28.8元
我武生物:4月28日召开业绩说明会,投资者参与
证券之星 · 04-28
我武生物:4月28日召开业绩说明会,投资者参与
我武生物:公司对于研发项目的投入是根据各研发项目进展合理规划投入
证券之星 · 04-23
我武生物:公司对于研发项目的投入是根据各研发项目进展合理规划投入
我武生物:深耕脱敏领域,保持国内领先地位
新浪证券 · 03-08
我武生物:深耕脱敏领域,保持国内领先地位
加载更多
公司概况
公司名称:
浙江我武生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2014-01-21
主营业务:
浙江我武生物科技股份有限公司是一家过敏性疾病诊断及治疗产品的研发、生产和销售的高新技术企业。公司主要产品包括粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂、粉尘螨皮肤点刺诊断试剂盒、屋尘螨皮肤点刺诊断试剂盒、“黄花蒿花粉变应原皮肤点刺液”、“白桦花粉变应原皮肤点刺液”、“葎草花粉变应原皮肤点刺液”。
发行价格:
20.05
{"stockData":{"symbol":"300357","market":"SZ","secType":"STK","nameCN":"我武生物","latestPrice":24.78,"timestamp":1715929389000,"preClose":24.56,"halted":0,"volume":5569128,"delay":0,"floatShares":484000000,"shares":524000000,"eps":0.6053,"marketStatus":"已收盘","marketStatusCode":5,"change":0.22,"latestTime":"05-17 15:00:00","open":24.58,"high":25.02,"low":24.53,"amount":138000000,"amplitude":0.02,"askPrice":24.79,"askSize":26,"bidPrice":24.78,"bidSize":116,"shortable":0,"etf":0,"ttmEps":0.6053,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716168600000},"adr":0,"adjPreClose":24.56,"symbolType":"stock","openAndCloseTimeList":[[1715909400000,1715916600000],[1715922000000,1715929200000]],"highLimit":27.02,"lowLimit":22.1,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":523584000,"pbRate":5.67,"roa":"--","roe":"3.47%","epsLYR":0.5924,"committee":0.088058,"marketValue":12974000000,"floatMarketCap":11995000000,"peRate":40.938377,"changeRate":0.009,"turnoverRate":0.0115,"status":0},"requestUrl":"/m/hq/s/300357/","defaultTab":"news","newsList":[{"id":"2435607993","title":"我武生物(300357)5月10日主力资金净卖出2688.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435607993","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435607993?lang=zh_cn&edition=full","pubTime":"2024-05-13 09:20","pubTimestamp":1715563220,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月10日收盘,我武生物报收于25.53元,下跌4.67%,换手率2.6%,成交量12.6万手,成交额3.27亿元。5月10日的资金流向数据方面,主力资金净流出2688.07万元,占总成交额8.21%,游资资金净流出966.29万元,占总成交额2.95%,散户资金净流入3654.36万元,占总成交额11.17%。融券方面,融券卖出10.96万股,融券偿还7.54万股,融券余量46.49万股,融券余额1186.88万元。我武生物主营业务:过敏性疾病诊断及治疗产品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051300001937.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434971858","title":"我武生物:公司2024年第一季度业绩有所恢复,具体经营情况详见2024年第一季度报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2434971858","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434971858?lang=zh_cn&edition=full","pubTime":"2024-05-10 20:01","pubTimestamp":1715342475,"startTime":"0","endTime":"0","summary":"证券之星消息,我武生物05月10日在投资者关系平台上答复投资者关心的问题。二季度以来是否延续了销售趋势我武生物董秘:投资者您好,公司2024年第一季度业绩有所恢复,具体经营情况详见2024年第一季度报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000042089.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434106440","title":"我武生物:公司子公司干细胞药物在研项目目前处于临床前研究阶段,不涉及糖尿病相关适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2434106440","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434106440?lang=zh_cn&edition=full","pubTime":"2024-05-09 18:02","pubTimestamp":1715248928,"startTime":"0","endTime":"0","summary":"证券之星消息,我武生物05月09日在投资者关系平台上答复投资者关心的问题。其他还有什么方向?公司子公司干细胞药物在研项目目前处于临床前研究阶段,不涉及糖尿病相关适应症。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900032785.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431905830","title":"西南证券:给予我武生物买入评级,目标价位28.8元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431905830","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431905830?lang=zh_cn&edition=full","pubTime":"2024-04-29 19:21","pubTimestamp":1714389718,"startTime":"0","endTime":"0","summary":"西南证券股份有限公司杜向阳,王彦迪近期对我武生物进行研究并发布了研究报告《一季度收入提速》,本报告对我武生物给出买入评级,认为其目标价位为28.80元,当前股价为24.1元,预期上涨幅度为19.5%。我武生物系我国脱敏药物龙头,给予公司2024年40倍PE,对应目标价为28.80元,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有5家机构给出评级,买入评级3家,增持评级2家;过去90天内机构目标均价为26.08。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900026071.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430032758","title":"我武生物:4月28日召开业绩说明会,投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2430032758","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430032758?lang=zh_cn&edition=full","pubTime":"2024-04-28 18:15","pubTimestamp":1714299319,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年4月28日我武生物发布公告称公司于2024年4月28日召开业绩说明会。2023 年公司营业收入和净利润小幅降低属于经营上的小幅波动。2024 年一季度,公司业务有所恢复,2024 年一季度,公司营业收入为 216,249,528.11 元,较上年同期增长18.08%。我武生物2024年一季报显示,公司主营收入2.16亿元,同比上升18.08%;归母净利润7720.73万元,同比上升9.55%;扣非净利润7254.44万元,同比上升6.8%;负债率9.19%,投资收益-36.38万元,财务费用-730.35万元,毛利率95.18%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042800007079.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429161021","title":"我武生物:公司对于研发项目的投入是根据各研发项目进展合理规划投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2429161021","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429161021?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:01","pubTimestamp":1713866508,"startTime":"0","endTime":"0","summary":"证券之星消息,我武生物(300357)04月23日在投资者关系平台上答复投资者关心的问题。投资者:请问公司研发金额增长速度,相比营收和利润是否增幅过快?我武生物董秘:投资者您好,公司对于研发项目的投入是根据各研发项目进展合理规划投入。感谢您的关注。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300035434.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417952080","title":"我武生物:深耕脱敏领域,保持国内领先地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2417952080","media":"新浪证券","top":-1,"share":"https://www.laohu8.com/m/news/2417952080?lang=zh_cn&edition=full","pubTime":"2024-03-08 17:45","pubTimestamp":1709891100,"startTime":"0","endTime":"0","summary":"3月8日,我武生物发布关于“质量回报双提升”行动方案的公告。公司表示,将继续巩固在现有过敏性疾病诊疗及延伸产品群中的优势,在该领域中发展相关及互补产品群:包括脱敏治疗产品及过敏诊断产品,不断完善“对因+对症”、“诊断+治疗”的过敏性疾病诊疗解决方案,确保公司在该领域的持续竞争优势。 2022 年,公司研发总投入金额为 116,665,722.78 元,占营业收入比例为13.02%。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:王其霖","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/2024-03-08/doc-inamrafk7943336.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/2024-03-08/doc-inamrafk7943336.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2014-01-21","address":"浙江省湖州市德清县武康镇志远北路636号","stockEarnings":[{"period":"1week","weight":-0.0294},{"period":"1month","weight":0.0965},{"period":"3month","weight":0.0077},{"period":"6month","weight":-0.1551},{"period":"1year","weight":-0.401},{"period":"ytd","weight":-0.1455}],"companyName":"浙江我武生物科技股份有限公司","boardCode":"AI0027","perCapita":"17652股","boardName":"医药制造业","registeredCapital":"52358万元","compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.0326},{"period":"1year","weight":-0.0435},{"period":"ytd","weight":0.0602}],"survey":" 浙江我武生物科技股份有限公司是一家过敏性疾病诊断及治疗产品的研发、生产和销售的高新技术企业。公司主要产品包括粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂、粉尘螨皮肤点刺诊断试剂盒、屋尘螨皮肤点刺诊断试剂盒、“黄花蒿花粉变应原皮肤点刺液”、“白桦花粉变应原皮肤点刺液”、“葎草花粉变应原皮肤点刺液”。","serverTime":1716071039459,"listedPrice":20.05,"stockholders":"27422人(较上一季度增加1.19%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"我武生物,300357,我武生物股票,我武生物股票老虎,我武生物股票老虎国际,我武生物行情,我武生物股票行情,我武生物股价,我武生物股市,我武生物股票价格,我武生物股票交易,我武生物股票购买,我武生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}